Andrew Kaplan - Surgery Partners Director
| SGRY Stock | USD 24.63 0.32 1.28% |
Director
Mr. Andrew T. Kaplan is an Independent Director of Surgery Partners since August 2018. Mr. Kaplan joined Bain Capital Private Equity in 2009. Prior to joining Bain Capital Private Equity, Mr. Kaplan was an investment banker with Goldman Sachs. He also cofounded EngagedHealth, LLC, a posthospitalization service for chronically ill, low income patients aiming to improve outcomes, reduce readmissions, and save costs. Mr. Kaplan has served on the Board of Directors for QuVa Pharma, Inc., since 2015 and BVO Holdings, LLC, since 2018 since 2018.
| Age | 33 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Address | 340 Seven Springs Way, Brentwood, TN, United States, 37027 |
| Phone | 615 234 5900 |
| Web | https://www.surgerypartners.com |
Andrew Kaplan Latest Insider Activity
Tracking and analyzing the buying and selling activities of Andrew Kaplan against Surgery Partners stock is an integral part of due diligence when investing in Surgery Partners. Andrew Kaplan insider activity provides valuable insight into whether Surgery Partners is net buyers or sellers over its current business cycle. Note, Surgery Partners insiders must abide by specific rules, including filing SEC forms every time they buy or sell Surgery Partners'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Andrew Kaplan over three months ago Sale by Andrew Kaplan of 7826870 shares of Surgery Partners |
Surgery Partners Management Efficiency
The company has return on total asset (ROA) of 0.0383 % which means that it generated a profit of $0.0383 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0407 %, meaning that it created $0.0407 on every $100 dollars invested by stockholders. Surgery Partners' management efficiency ratios could be used to measure how well Surgery Partners manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 0.07 in 2024, whereas Return On Tangible Assets are likely to drop (0) in 2024. At this time, Surgery Partners' Non Currrent Assets Other are fairly stable compared to the past year. Intangibles To Total Assets is likely to rise to 0.76 in 2024, whereas Total Assets are likely to drop slightly above 4.6 B in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Christopher Reidy | Encompass Health Corp | 64 | |
| Reeve Waud | Acadia Healthcare | 54 | |
| Donald Correll | Encompass Health Corp | 70 | |
| Yvonne Curl | Encompass Health Corp | 65 | |
| Edward Shaw | Encompass Health Corp | 73 | |
| Hartley Rogers | Acadia Healthcare | 56 | |
| Kyle Lattner | Acadia Healthcare | 29 | |
| Wade Miquelon | Acadia Healthcare | 53 | |
| Charles Elson | Encompass Health Corp | 60 | |
| William Petrie | Acadia Healthcare | 71 | |
| John Chidsey | Encompass Health Corp | 58 | |
| William Grieco | Acadia Healthcare | 64 | |
| EPerot Bissell | Acadia Healthcare | 58 | |
| Leslye Katz | Encompass Health Corp | 66 | |
| Joan Herman | Encompass Health Corp | 67 | |
| Christopher Gordon | Acadia Healthcare | 44 | |
| Nancy Schlichting | Encompass Health Corp | 66 | |
| Vicky Gregg | Acadia Healthcare | 63 | |
| John Maupin | Encompass Health Corp | 73 | |
| Chris Gordon | Acadia Healthcare | 44 | |
Management Performance
| Return On Equity | 0.0407 | ||||
| Return On Asset | 0.0383 |
Surgery Partners Leadership Team
Elected by the shareholders, the Surgery Partners' board of directors comprises two types of representatives: Surgery Partners inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Surgery. The board's role is to monitor Surgery Partners' management team and ensure that shareholders' interests are well served. Surgery Partners' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Surgery Partners' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Doherty, Executive CFO | ||
| Bradley Owens, President Group | ||
| Adam Feinstein, Independent Director | ||
| Christopher Laitala, Independent Chairman of the Board | ||
| Teresa DeLuca, Director | ||
| Bryan Fisher, COO, Executive Vice President | ||
| Harrison Bane, President Group | ||
| Michael Doyle, CEO, Director | ||
| Jennifer Baldock, Senior Vice President General Counsel, Secretary | ||
| Andrew Kaplan, Director | ||
| Thomas Cowhey, CFO, Principal Accounting Officer | ||
| Teresa Sparks, CFO, Executive Vice President | ||
| Christopher Gordon, Director | ||
| David Kretschmer, Chief Strategy and Transformation Officer and interim CFO | ||
| Neil Zieselman, Senior Controller | ||
| Carollee Brinkman, President - National Group | ||
| Brent Turner, Director | ||
| Varun Gadhok, Senior Officer | ||
| Angela Justice, Chief Human Resource Officer | ||
| Danielle Burkhalter, Chief Officer | ||
| George Goodwin, President - American Group | ||
| Clifford Adlerz, Interim CEO, Director | ||
| Matthew Lozow, Independent Director | ||
| Wayne DeVeydt, Executive Chairman | ||
| Dennis Dean, Senior Vice President Corporate Controller | ||
| John Deane, Independent Director | ||
| Roxanne Womack, Senior Officer | ||
| Brandan Lingle, Group President of Ancillary Services | ||
| John Crysel, Group President of Surgery Partners’ National Group | ||
| Devin OReilly, Director | ||
| Eric Evans, COO, Executive Vice President | ||
| Marissa Brittenham, Ex Officer | ||
| Anthony Taparo, President - Atlantic Group | ||
| Ronald Zelhof, Senior Vice President - Operation |
Surgery Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Surgery Partners a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0407 | ||||
| Return On Asset | 0.0383 | ||||
| Profit Margin | (0) % | ||||
| Operating Margin | 0.20 % | ||||
| Current Valuation | 7.4 B | ||||
| Shares Outstanding | 127.1 M | ||||
| Shares Owned By Insiders | 1.09 % | ||||
| Shares Owned By Institutions | 98.91 % | ||||
| Number Of Shares Shorted | 8.6 M | ||||
| Price To Earning | 61.84 X |
Surgery Partners Investors Sentiment
The influence of Surgery Partners' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Surgery. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Surgery Partners' public news can be used to forecast risks associated with an investment in Surgery. The trend in average sentiment can be used to explain how an investor holding Surgery can time the market purely based on public headlines and social activities around Surgery Partners. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Surgery Partners' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Surgery Partners' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Surgery Partners' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Surgery Partners.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Surgery Partners in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Surgery Partners' short interest history, or implied volatility extrapolated from Surgery Partners options trading.
Currently Active Assets on Macroaxis
When determining whether Surgery Partners offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Surgery Partners' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Surgery Partners Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Surgery Partners Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Surgery Partners. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Surgery Stock please use our How to Invest in Surgery Partners guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Surgery Stock analysis
When running Surgery Partners' price analysis, check to measure Surgery Partners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Surgery Partners is operating at the current time. Most of Surgery Partners' value examination focuses on studying past and present price action to predict the probability of Surgery Partners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Surgery Partners' price. Additionally, you may evaluate how the addition of Surgery Partners to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |
Is Surgery Partners' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Surgery Partners. If investors know Surgery will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Surgery Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.09) | Revenue Per Share 21.839 | Quarterly Revenue Growth 0.04 | Return On Assets 0.0383 | Return On Equity 0.0407 |
The market value of Surgery Partners is measured differently than its book value, which is the value of Surgery that is recorded on the company's balance sheet. Investors also form their own opinion of Surgery Partners' value that differs from its market value or its book value, called intrinsic value, which is Surgery Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Surgery Partners' market value can be influenced by many factors that don't directly affect Surgery Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Surgery Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Surgery Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Surgery Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.